ArticleBiosensors & bioelectronics2008
Peptide-coated nanotube-based biosensor for the detection of disease-specific autoantibodies in human serum.
Article in Biosensors & bioelectronics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 92 citations in OpenAlex.
- Peptide-Coated Bacteriorhodopsin-Based Photoelectric Biosensor for Detecting Rheumatoid Arthritis.Biosensors · 2023Article
- Immunosensors for Autoimmune-Disease-Related Biomarkers: A Literature Review.Sensors (Basel, Switzerland) · 2023Review
- An Overview of High Frequency Acoustic Sensors-QCMs, SAWs and FBARs-Chemical and Biochemical Applications.Sensors (Basel, Switzerland) · 2019Review
- An SPR Sensor Chip Based on Peptide-Modified Single-Walled Carbon Nanotubes with Enhanced Sensitivity and Selectivity in the Detection of 2,4,6-Trinitrotoluene Explosives.Sensors (Basel, Switzerland) · 2018Article
- Construction and Potential Applications of Biosensors for Proteins in Clinical Laboratory Diagnosis.Sensors (Basel, Switzerland) · 2017Review
- Carbon Nanomaterial Based Biosensors for Non-Invasive Detection of Cancer and Disease Biomarkers for Clinical Diagnosis.Sensors (Basel, Switzerland) · 2017Review
- Enzymatically Regulated Peptide Pairing and Catalysis for the Bioanalysis of Extracellular Prometastatic Activities of Functionally Linked Enzymes.Scientific reports · 2016Article
- Post-genomics nanotechnology is gaining momentum: nanoproteomics and applications in life sciences.Omics : a journal of integrative biology · 2014Review
- Biomarker discovery by novel sensors based on nanoproteomics approaches.Sensors (Basel, Switzerland) · 2012Review
- Biosensors in clinical chemistry - 2011 update.Clinica chimica acta; international journal of clinical chemistry · 2011Review
- Label-free detection techniques for protein microarrays: prospects, merits and challenges.Proteomics · 2010Review
- Cell culture on MEMS platforms: a review.International journal of molecular sciences · 2009Review
- Concurrent detection of secreted products from human lymphocytes by microengraving: cytokines and antigen-reactive antibodies.Clinical immunology (Orlando, Fla.) · 2008Article
- BioMEMS -Advancing the Frontiers of Medicine.Sensors (Basel, Switzerland) · 2008Review
- Current trends in nanobiosensor technology.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
We demonstrate a label-free peptide-coated carbon nanotube-based immunosensor for the direct assay of human serum. A rheumatoid arthritis (RA)-specific (cyclic citrulline-containing) peptide, was immobilized to functionalized single-walled carbon nanotubes deposited on a quartz crystal microbalance (QCM) sensing crystal. Serum from RA patients was used to probe these nanotube-based sensors, and antibody binding was detected by QCM sensing. Specific antibody binding was also determined by comparing the assay of two serum control groups (normal and diseased sera), and the native unmodified peptide. The sensitivity of the nanotube-based sensor (detection in the femtomol range) was higher than that of the established ELISA and recently described microarray assay systems, detecting 34.4 and 37.5% more RA patients with anti-citrullinated peptide antibodies than those found by ELISA and microarray, respectively. There was also an 18.4 and 19.6% greater chance of a negative test being a true indicator of a person not having RA than by either ELISA or microarray, respectively. The performance of our label-free biosensor enables its application in the direct assay of sera in research and diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.